

Medical abortion at 10-20 weeks

Submission date 22/08/2013	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 02/10/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 17/12/2024	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Two drugs, mifepristone and misoprostol, are authorized to use for the termination of an early pregnancy only, although they are recommended as the best and safest method by the World Health Organization, and also used, unlicensed, for the termination of later stages of pregnancies. Clinical trial data is needed for registration but these data are not currently available. The purpose of this study is to demonstrate how this drug regimen works and how to use the information to officially register the method.

Who can participate?

Women who are 64 to 140 days pregnant can participate in the study.

What does the study involve?

Women will first get a pill of mifepristone to swallow, and when they return to the hospital one or two days later, they will be given the second drug, misoprostol. They may need two to three doses of misoprostol. They are given at 3-hour intervals, before the pregnancy is terminated.

What are the possible benefits and risks of participating?

Some women prefer medical abortion to surgical abortion so this study may give them this choice. Most women in the study can be expected to have a complete abortion and will not be exposed to some of the risks associated with surgical abortion, particularly the risk of physical distress. By participating in the study women do not increase their risks associated with the termination of pregnancy.

Where is the study run from?

The study will be run from eight hospitals in India, Sweden, Thailand and Vietnam.

When is the study starting and how long is it expected to run for?

We expect to start the study by the end of 2013 and it is expected to last for 12-14 months.

Who is funding the study?

Concept Foundation, Geneva, Switzerland.

Who is the main contact?
Dr Helena von Hertzen
helena.vonhertzen@gmail.com

Contact information

Type(s)
Scientific

Contact name
Dr Helena von Hertzen

Contact details
46 Route de Montfleury
Geneva
Switzerland
1214

Additional identifiers

Clinical Trials Information System (CTIS)
2013-004294-27

Protocol serial number
N/A

Study information

Scientific Title
Termination Of Pregnancy at 64-140 days

Acronym
TOP

Study objectives
Administration of misoprostol 24 h after mifepristone is non-inferior in efficacy, measured as abortion rate at 24 h, to administration of misoprostol 48 h after mifepristone, assuming that this rate in both interval groups will be about 96%-97% and within an inferiority margin of 5%.

Ethics approval required
Old ethics approval format

Ethics approval(s)
1. Institutional Review Board, Faculty of Medicine, Chulalongkorn University, Thailand, 20/03/2014
2. Committee on Human Rights Related to Research Involving Human Subjects, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand, 22/01/2014
3. Siriraj Institutional Review Board, Thailand, 21/05/2014

Study design

International multicentre trial

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Pregnancy of 64-140 days duration

Interventions

Women are randomized to receive misoprostol treatment (orally) (as in WHO Safe abortion guidelines, 2012) either 24 hours or 48 hours after mifepristone.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Misoprostol, Mifepristone

Primary outcome(s)

Efficacy (expulsion of pregnancy) at 24 h

Key secondary outcome(s)

1. Induction-to-abortion interval: This is the time interval from the administration of the first dose of misoprostol until expulsion of the products of conception
2. Possible side-effects: Side effects are recorded during the whole study, from the administration of mifepristone until the follow-up visit, or beyond, if needed
3. Women's perceptions: Women's perception of the method are recorded at an interview during the follow-up visit about two weeks after treatment

Completion date

30/06/2015

Eligibility**Key inclusion criteria**

1. Good general health
2. Older than the age for legal consent
3. Requesting and eligible for legal termination of pregnancy
4. Duration of pregnancy 64-140 days on Day 1 (mifepristone administration), verified by ultrasound

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

1. No contra-indications towards mifepristone and misoprostol
2. No serious present or past ill health
3. Molar or extrauterine pregnancy or threatend abortion, >1 low segment C-section

Date of first enrolment

01/01/2014

Date of final enrolment

30/06/2015

Locations**Countries of recruitment**

India

Sweden

Switzerland

Thailand

Viet Nam

Study participating centre

46 Route de Montfleury

Geneva

Switzerland

1214

Sponsor information**Organisation**

Concept Foundation (Switzerland)

ROR

Funder(s)

Funder type
Charity

Funder Name
Concept Foundation (Switzerland)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Protocol file		03/10/2013	17/12/2024	No	No